Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 128Magnetic Resonance Spectroscopy 105Biopsy 76pembrolizumab 63Nivolumab 60Carboplatin 59Cisplatin 57Cyclophosphamide 53Paclitaxel 44Radiotherapy 36Bevacizumab 36Gemcitabine 34Dexamethasone 33Rituximab 26Doxorubicin 26olaparib 25Pemetrexed 25Fluorouracil 25atezolizumab 24Radiation 24Injections 23Docetaxel 23fludarabine 22durvalumab 22Vincristine 21Prednisone 21Oxaliplatin 21Ipilimumab 21Cytarabine 21venetoclax 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neurokinin-1 Receptor Antagonists × 30 days × Clear all
NCT06780085 2026-05-26

MK-3475-01H

Merck Sharp & Dohme LLC

Phase 2 Recruiting
96 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡